Originally published by our sister publication Gastroenterology & Endoscopy News
By Marcus A. Banks
WASHINGTON—Machine learning tools can sift through genetic profiles to predict which patients with obesity will best respond to glucagon-like peptide-1 agonists such as liraglutide (Saxenda/Victoza, Novo Nordisk) or semaglutide (Ozempic/Wegovy, Novo Nordisk), according to a presentation by Mayo Clinic researchers at DDW 2024.
Mayo researchers previously had found that patients with obesity